Relmada Therapeutics, Inc. - Common Stock — Cash Flow (NASDAQ:RLMD) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Cash from operating activities -27.81 M-91.87 M-103.8 M-51.66 M-51.76 M-45.79 M -45.99 M Cash from investing activities -34.45 M-54.12 M19.73 M50.45 M51.56 M-48.14 M -187.82 M Cash from financing activities 28.47 M187.94 M45.02 M-98.46 K-40.34 K93.56 M 243.79 M Free cash flow -209.86 M-91.87 M-103.8 M-51.66 M-51.76 M-45.79 M -45.99 M

News

Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now

Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround

Relmada: NDV-01 Entering Phase 3 In NMIBC; No Rush To Buy Stock Today (NASDAQ:RLMD)

Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call - Relmada Therapeutics (NASDAQ:RLMD)

Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript

Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect?

Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics

5 Small Drug Stocks to Buy as Sector Recovery Gains Strength

Relmada Therapeutics: 2 New Assets, 2 New 'Blockbusters'? I'd Wait And See (NASDAQ:RLMD)

Wall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should Know

Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call Transcript

Mizuho reiterates Relmada stock rating on positive cancer trial data